Video

Finding the Right Therapy for High-Risk Mantle Cell Lymphoma

A certain group of patients may not be candidates for common therapies, explained Bijal D. Shah, M.D.

Patients with high-risk mantle cell lymphoma may also have more proliferative disease and carry P53 mutations, and in turn, could experience worse outcomes when treated with common therapies, explained Bijal D. Shah, M.D., oncologist at the Moffitt Cancer Center.

Experts in the field have described this group of patients as a "distinct subtype" of mantle cell lymphoma, and studies have shown that despite the fact that these patients may be younger, they tend to have worse outcomes when given regimens of high-dose induction therapy followed by a stem cell transplant.

So, it is important that researchers and clinicians alike continue to search for better therapies for these patients.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.